RxDoctor Payments Data

Amy Fisher, PA

Medical · Murray, UTNPI 1164176772

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,569 of the $4,011 with a category attached, or 64.1%. Relievant Medsystems, Inc. accounts for 63.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $1,992 and has fallen 97.5% since, to $50 in 2025.

$4,011in general payments, 2019–2025

Across 57 payments — averaging $70.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$3K
  • Abbott$813
  • Collegium Pharmaceutical, Inc.$151
  • Nalu Medical, Inc.$73
  • Boston Scientific$68
  • Medtronic$49
  • plus $322 from 11 others

What the payments were for

  • Travel & lodging$2,56964%
  • Food & beverage$1,44236%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,011 in reported general payments places this provider in the 85th percentile of 263 medical providers in Utah.

See all medical providers in Utah

Medicare billing

Part B allowed, 2024
$14,901
Medicare patients
97
Services billed
506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen455$12,172
MovantikNaloxegol Oxalate29$11,314
BelbucaBuprenorphine Hcl12$11,196
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen235$11,163
Buprenorphine Hcl138$9,102
Buprenorphine23$7,686
MeloxicamMeloxicam, Submicronized12$6,622
Morphine Sulfate ErMorphine Sulfate76$4,108
Gabapentin191$3,443
Fentanyl28$3,100
Pregabalin47$2,339
Oxycodone Hcl97$2,144
Tramadol Hcl110$1,536
Tizanidine Hcl87$1,008
Celecoxib59$998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$151$11,19612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 263 medical providers in Utah.

Other medical in Murray

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →